The efficacy of MLC 901 in neuron-specific enolase, functional outcome and cerebral infarct volume for acute ischemic stroke model in rats.

Abstract

BACKGROUND: Ischemia causes neuronal death and releases Neuron-Specific Enolase (NSE). Thrombolysis is a standard therapy for ischemic stroke, but only 10-20 percent of patients receive thrombolysis. It is necessary to develop a treatment to increase neuroprotection by administering MLC 901 to influence NSE levels. OBJECTIVES: The study investigates the efficacy of MLC 901 on NSE levels, functional outcome and infarct volume in the stroke model of rats. METHODS: Male Wistar rats were divided into acute ischemic stroke with MLC 901 43.2 mg/body weight, acute ischemic stroke with MLC 901 21.6 mg/body weight and acute ischemic stroke with CMC-Na for placebo-all treatment for 14 days. The NSE level was determined by ELISA, functional outcome determined by motoric score and infarct volume using NIH Image J. RESULTS: NSE level increased at 24 hours after stroke. There was no difference in administering the dose of MLC 901 to improve functional outcome and reduce cerebral infarct volume. CONCLUSION: MLC 901 improved functional outcomes and reduced the volume of cerebral infarction in acute ischemic stroke but did not affect NSE levels.